ABBV vs ORCL: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Oracle Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-18.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Oracle Corporation · Technology
$175.08
+24.7% upside to fair value
Grade B
QuantHub Verdict
ORCL has more upside to fair value
(+24.7%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
ORCL |
| Current Price |
$208.05 |
$175.08 |
| Fair Value Estimate |
$217.50 |
$218.26 |
| Upside to Fair Value |
+4.5%
|
+24.7%
|
| Market Cap |
$367.9B |
$503.5B |
| Forward P/E |
14.9x
|
30.8x
|
| EV / EBITDA |
16.7x
|
21.4x
|
| Price / Sales |
6.1x
|
7.9x
|
| Price / FCF |
20.9x
|
-20.4x
|
| Revenue Growth YoY |
+8.6%
|
+7.0%
|
| Gross Margin |
83.7%
|
66.4%
|
| Operating Margin |
34.7%
|
30.8%
|
| Return on Equity |
-129.24%
|
57.4%
|
| Dividend Yield |
3.2% |
0% |
| FCF Yield |
4.78%
|
—
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Oracle Corporation is a leading technology company specializing in software infrastructure, with a dominant Cloud and License Business segment generating 85.8% of its $57.4 billion revenue in fiscal 2025. The company benefits from a durable competitive moat driven by decades of leadership continuity, aggressive M&A history, and a strong position in enterprise software and cloud services. Despite …
Accumulation Zones
| Metric |
ABBV |
ORCL |
| Zone Low |
$163.13 |
$163.69 |
| Zone High |
$184.88 |
$185.52 |
| In Buy Zone? |
No
|
Yes
|